Journal of General Virology, Vol 79, 1159-1167, Copyright © 1998 by Society for General Microbiology

ARTICLES

Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine

TJ Blanchard, A Alcami, P Andrea and GL Smith
Sir William Dunn School of Pathology, University of Oxford, UK.

Modified virus Ankara (MVA) is a vaccinia virus (VV) strain that was attenuated by serial passage through chick embryo fibroblasts (CEFs) and contains six large genomic deletions compared with parental virus. MVA replicates well in CEFs, but poorly in most mammalian cells. Recombinant MVA is a promising human vaccine candidate due to its restricted host range, immunogenicity and avirulence in animal models, and excellent safety record as a smallpox vaccine. Here we present a further characterization of MVA and demonstrate that: (i) MVA can replicate, albeit poorly, in transformed human cell lines, but not in primary human fibroblasts although there is limited cell-to-cell spread; (ii) MVA is a potent inducer of type I interferon (IFN) from primary human cells, which may restrict virus spread in vivo; and (iii) unlike other VV strains, MVA does not express soluble receptors for IFN- gamma, IFN-alpha/beta, tumour necrosis factor and CC chemokines, but does express a soluble interleukin-1beta receptor. This provides a plausible and testable explanation for the good immunogenicity of MVA despite its poor replication in mammals. The implications of these findings for the use of MVA as a safe and immunogenic human vaccine candidate are discussed.

This article has been cited by other articles:

				P. L. Earl, J. L. Americo, L. S. Wyatt, O. Espenshade, J. Bassler, K. Gong, S. Lin, E. Peters, L. Rhodes Jr, Y. E. Spano, et al. Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus PNAS, August 5, 2008; 105(31): 10889 - 10894. [Abstract] [Full Text] [PDF]

				Z. Waibler, M. Anzaghe, H. Ludwig, S. Akira, S. Weiss, G. Sutter, and U. Kalinke Modified Vaccinia Virus Ankara Induces Toll-Like Receptor-Independent Type I Interferon Responses J. Virol., November 15, 2007; 81(22): 12102 - 12110. [Abstract] [Full Text] [PDF]

				I. G. Sakala, G. Chaudhri, R. M. Buller, A. A. Nuara, H. Bai, N. Chen, and G. Karupiah Poxvirus-Encoded Gamma Interferon Binding Protein Dampens the Host Immune Response to Infection J. Virol., April 1, 2007; 81(7): 3346 - 3353. [Abstract] [Full Text] [PDF]

				C. Staib, Y. Suezer, S. Kisling, U. Kalinke, and G. Sutter Short-term, but not post-exposure, protection against lethal orthopoxvirus challenge after immunization with modified vaccinia virus Ankara. J. Gen. Virol., October 1, 2006; 87(Pt 10): 2917 - 2921. [Abstract] [Full Text] [PDF]

				J. O. Langland, J. C. Kash, V. Carter, M. J. Thomas, M. G. Katze, and B. L. Jacobs Suppression of Proinflammatory Signal Transduction and Gene Expression by the Dual Nucleic Acid Binding Domains of the Vaccinia Virus E3L Proteins. J. Virol., October 1, 2006; 80(20): 10083 - 10095. [Abstract] [Full Text] [PDF]

				G. S. Taylor, H. M. Long, T. A. Haigh, M. Larsen, J. Brooks, and A. B. Rickinson A Role for Intercellular Antigen Transfer in the Recognition of EBV-Transformed B Cell Lines by EBV Nuclear Antigen-Specific CD4+ T Cells J. Immunol., September 15, 2006; 177(6): 3746 - 3756. [Abstract] [Full Text] [PDF]

				R. Chavan, K. A. Marfatia, I. C. An, D. A. Garber, and M. B. Feinberg Expression of CCL20 and Granulocyte-Macrophage Colony-Stimulating Factor, but Not Flt3-L, from Modified Vaccinia Virus Ankara Enhances Antiviral Cellular and Humoral Immune Responses. J. Virol., August 1, 2006; 80(15): 7676 - 7687. [Abstract] [Full Text] [PDF]

				M. G. Cottingham, A. van Maurik, M. Zago, A. T. Newton, R. J. Anderson, M. K. Howard, J. Schneider, and M. A. Skinner Different Levels of Immunogenicity of Two Strains of Fowlpox Virus as Recombinant Vaccine Vectors Eliciting T-Cell Responses in Heterologous Prime-Boost Vaccination Strategies. Clin. Vaccine Immunol., July 1, 2006; 13(7): 747 - 757. [Abstract] [Full Text] [PDF]

				H. Ludwig, Y. Suezer, Z. Waibler, U. Kalinke, B. S. Schnierle, and G. Sutter Double-stranded RNA-binding protein E3 controls translation of viral intermediate RNA, marking an essential step in the life cycle of modified vaccinia virus Ankara. J. Gen. Virol., May 1, 2006; 87(Pt 5): 1145 - 1155. [Abstract] [Full Text] [PDF]

				M. I. Okeke, O. Nilssen, and T. Traavik Modified vaccinia virus Ankara multiplies in rat IEC-6 cells and limited production of mature virions occurs in other mammalian cell lines J. Gen. Virol., January 1, 2006; 87(1): 21 - 27. [Abstract] [Full Text] [PDF]

				R. H. Clark, J. C. Kenyon, N. W. Bartlett, D. C. Tscharke, and G. L. Smith Deletion of gene A41L enhances vaccinia virus immunogenicity and vaccine efficacy J. Gen. Virol., January 1, 2006; 87(1): 29 - 38. [Abstract] [Full Text] [PDF]

				C. Palena, K. A. Foon, D. Panicali, A. G. Yafal, J. Chinsangaram, J. W. Hodge, J. Schlom, and K. Y. Tsang Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules Blood, November 15, 2005; 106(10): 3515 - 3523. [Abstract] [Full Text] [PDF]

				M. M. Gherardi and M. Esteban Recombinant poxviruses as mucosal vaccine vectors J. Gen. Virol., November 1, 2005; 86(11): 2925 - 2936. [Abstract] [Full Text] [PDF]

				G. Li, N. Chen, R. L. Roper, Z. Feng, A. Hunter, M. Danila, E. J. Lefkowitz, R. M. L. Buller, and C. Upton Complete coding sequences of the rabbitpox virus genome J. Gen. Virol., November 1, 2005; 86(11): 2969 - 2977. [Abstract] [Full Text] [PDF]

				D. J. Esteban and R. M. L. Buller Ectromelia virus: the causative agent of mousepox J. Gen. Virol., October 1, 2005; 86(10): 2645 - 2659. [Abstract] [Full Text] [PDF]

				C. Staib, S. Kisling, V. Erfle, and G. Sutter Inactivation of the viral interleukin 1{beta} receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara J. Gen. Virol., July 1, 2005; 86(7): 1997 - 2006. [Abstract] [Full Text] [PDF]

				C. L. Hutchings, S. C. Gilbert, A. V. S. Hill, and A. C. Moore Novel Protein and Poxvirus-Based Vaccine Combinations for Simultaneous Induction of Humoral and Cell-Mediated Immunity J. Immunol., July 1, 2005; 175(1): 599 - 606. [Abstract] [Full Text] [PDF]

				S. Buchan, E. Gronevik, I. Mathiesen, C. A. King, F. K. Stevenson, and J. Rice Electroporation as a "Prime/Boost" Strategy for Naked DNA Vaccination against a Tumor Antigen J. Immunol., May 15, 2005; 174(10): 6292 - 6298. [Abstract] [Full Text] [PDF]

				H. Ludwig, J. Mages, C. Staib, M. H. Lehmann, R. Lang, and G. Sutter Role of Viral Factor E3L in Modified Vaccinia Virus Ankara Infection of Human HeLa Cells: Regulation of the Virus Life Cycle and Identification of Differentially Expressed Host Genes J. Virol., February 15, 2005; 79(4): 2584 - 2596. [Abstract] [Full Text] [PDF]

				L. H. McCurdy, J. A. Rutigliano, T. R. Johnson, M. Chen, and B. S. Graham Modified Vaccinia Virus Ankara Immunization Protects against Lethal Challenge with Recombinant Vaccinia Virus Expressing Murine Interleukin-4 J. Virol., November 15, 2004; 78(22): 12471 - 12479. [Abstract] [Full Text] [PDF]

				F. K. Stevenson, C. H. Ottensmeier, P. Johnson, D. Zhu, S. L. Buchan, K. J. McCann, J. S. Roddick, A. T. King, F. McNicholl, N. Savelyeva, et al. DNA vaccines to attack cancer PNAS, October 5, 2004; 101(suppl_2): 14646 - 14652. [Abstract] [Full Text] [PDF]

				R. Drillien, D. Spehner, and D. Hanau Modified vaccinia virus Ankara induces moderate activation of human dendritic cells J. Gen. Virol., August 1, 2004; 85(8): 2167 - 2175. [Abstract] [Full Text] [PDF]

				B. Makitalo, P. Lundholm, J. Hinkula, C. Nilsson, K. Karlen, A. Morner, G. Sutter, V. Erfle, J. L. Heeney, B. Wahren, et al. Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen J. Gen. Virol., August 1, 2004; 85(8): 2407 - 2419. [Abstract] [Full Text] [PDF]

				S. Guerra, L. A. Lopez-Fernandez, R. Conde, A. Pascual-Montano, K. Harshman, and M. Esteban Microarray Analysis Reveals Characteristic Changes of Host Cell Gene Expression in Response to Attenuated Modified Vaccinia Virus Ankara Infection of Human HeLa Cells J. Virol., June 1, 2004; 78(11): 5820 - 5834. [Abstract] [Full Text] [PDF]

				M. Franchini, H. Hefti, S. Vollstedt, B. Glanzmann, M. Riesen, M. Ackermann, P. Chaplin, K. Shortman, and M. Suter Dendritic Cells from Mice Neonatally Vaccinated with Modified Vaccinia Virus Ankara Transfer Resistance against Herpes Simplex Virus Type I to Naive One-Week-Old Mice J. Immunol., May 15, 2004; 172(10): 6304 - 6312. [Abstract] [Full Text] [PDF]

				H. Bisht, A. Roberts, L. Vogel, A. Bukreyev, P. L. Collins, B. R. Murphy, K. Subbarao, and B. Moss Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice PNAS, April 27, 2004; 101(17): 6641 - 6646. [Abstract] [Full Text] [PDF]

				E. Ramsburg, N. F. Rose, P. A. Marx, M. Mefford, D. F. Nixon, W. J. Moretto, D. Montefiori, P. Earl, B. Moss, and J. K. Rose Highly Effective Control of an AIDS Virus Challenge in Macaques by Using Vesicular Stomatitis Virus and Modified Vaccinia Virus Ankara Vaccine Vectors in a Single-Boost Protocol J. Virol., April 15, 2004; 78(8): 3930 - 3940. [Abstract] [Full Text] [PDF]

				L. S. Wyatt, P. L. Earl, L. A. Eller, and B. Moss Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge PNAS, March 30, 2004; 101(13): 4590 - 4595. [Abstract] [Full Text] [PDF]

				J. W. Hodge, D. J. Poole, W. M. Aarts, A. Gomez Yafal, L. Gritz, and J. Schlom Modified Vaccinia Virus Ankara Recombinants Are as Potent as Vaccinia Recombinants in Diversified Prime and Boost Vaccine Regimens to Elicit Therapeutic Antitumor Responses Cancer Res., November 15, 2003; 63(22): 7942 - 7949. [Abstract] [Full Text] [PDF]

				G. Gonzalez-Aseguinolaza, Y. Nakaya, A. Molano, E. Dy, M. Esteban, D. Rodriguez, J. R. Rodriguez, P. Palese, A. Garcia-Sastre, and R. S. Nussenzweig Induction of Protective Immunity against Malaria by Priming-Boosting Immunization with Recombinant Cold-Adapted Influenza and Modified Vaccinia Ankara Viruses Expressing a CD8+-T-Cell Epitope Derived from the Circumsporozoite Protein of Plasmodium yoelii J. Virol., November 1, 2003; 77(21): 11859 - 11866. [Abstract] [Full Text] [PDF]

				J. C. Gallego-Gomez, C. Risco, D. Rodriguez, P. Cabezas, S. Guerra, J. L. Carrascosa, and M. Esteban Differences in Virus-Induced Cell Morphology and in Virus Maturation between MVA and Other Strains (WR, Ankara, and NYCBH) of Vaccinia Virus in Infected Human Cells J. Virol., October 1, 2003; 77(19): 10606 - 10622. [Abstract] [Full Text] [PDF]

				S. Hornemann, O. Harlin, C. Staib, S. Kisling, V. Erfle, B. Kaspers, G. Hacker, and G. Sutter Replication of Modified Vaccinia Virus Ankara in Primary Chicken Embryo Fibroblasts Requires Expression of the Interferon Resistance Gene E3L J. Virol., August 1, 2003; 77(15): 8394 - 8407. [Abstract] [Full Text] [PDF]

				X. Wang, M. Messerle, R. Sapinoro, K. Santos, P. K. Hocknell, X. Jin, and S. Dewhurst Murine Cytomegalovirus Abortively Infects Human Dendritic Cells, Leading to Expression and Presentation of Virally Vectored Genes J. Virol., July 1, 2003; 77(13): 7182 - 7192. [Abstract] [Full Text] [PDF]

				J. Espenschied, J. Lamont, J. Longmate, S. Pendas, Z. Wang, D. J. Diamond, and J. D. I. Ellenhorn CTLA-4 Blockade Enhances the Therapeutic Effect of an Attenuated Poxvirus Vaccine Targeting p53 in an Established Murine Tumor Model J. Immunol., March 15, 2003; 170(6): 3401 - 3407. [Abstract] [Full Text] [PDF]

				K. K. A. Van Rompay, J. L. Greenier, K. S. Cole, P. Earl, B. Moss, J. D. Steckbeck, B. Pahar, T. Rourke, R. C. Montelaro, D. R. Canfield, et al. Immunization of Newborn Rhesus Macaques with Simian Immunodeficiency Virus (SIV) Vaccines Prolongs Survival after Oral Challenge with Virulent SIVmac251 J. Virol., December 6, 2002; 77(1): 179 - 190. [Abstract] [Full Text] [PDF]

				J. A. Symons, D. C. Tscharke, N. Price, and G. L. Smith A study of the vaccinia virus interferon-{gamma} receptor and its contribution to virus virulence J. Gen. Virol., August 1, 2002; 83(8): 1953 - 1964. [Abstract] [Full Text] [PDF]

				D. C. Tscharke, P. C. Reading, and G. L. Smith Dermal infection with vaccinia virus reveals roles for virus proteins not seen using other inoculation routes J. Gen. Virol., August 1, 2002; 83(8): 1977 - 1986. [Abstract] [Full Text] [PDF]

				R. R. Amara, F. Villinger, S. I. Staprans, J. D. Altman, D. C. Montefiori, N. L. Kozyr, Y. Xu, L. S. Wyatt, P. L. Earl, J. G. Herndon, et al. Different Patterns of Immune Responses but Similar Control of a Simian-Human Immunodeficiency Virus 89.6P Mucosal Challenge by Modified Vaccinia Virus Ankara (MVA) and DNA/MVA Vaccines J. Virol., June 27, 2002; 76(15): 7625 - 7631. [Abstract] [Full Text] [PDF]

				C. Nilsson, G. Sutter, L. Walther-Jallow, P. ten Haaft, L. Akerblom, J. Heeney, V. Erfle, P. Bottiger, G. Biberfeld, and R. Thorstensson Immunization with recombinant modified vaccinia virus Ankara can modify mucosal simian immunodeficiency virus infection and delay disease progression in macaques J. Gen. Virol., April 1, 2002; 83(4): 807 - 818. [Abstract] [Full Text] [PDF]

				H. McShane, R. Brookes, S. C. Gilbert, and A. V. S. Hill Enhanced Immunogenicity of CD4+ T-Cell Responses and Protective Efficacy of a DNA-Modified Vaccinia Virus Ankara Prime-Boost Vaccination Regimen for Murine Tuberculosis Infect. Immun., February 1, 2001; 69(2): 681 - 686. [Abstract] [Full Text] [PDF]

				A. P. Durbin, M. H. Skiadopoulos, J. M. McAuliffe, J. M. Riggs, S. R. Surman, P. L. Collins, and B. R. Murphy Human Parainfluenza Virus Type 3 (PIV3) Expressing the Hemagglutinin Protein of Measles Virus Provides a Potential Method for Immunization against Measles Virus and PIV3 in Early Infancy J. Virol., August 1, 2000; 74(15): 6821 - 6831. [Abstract] [Full Text]

				V. P. Smith, N. A. Bryant, and A. Alcamí Ectromelia, vaccinia and cowpox viruses encode secreted interleukin-18-binding proteins J. Gen. Virol., May 1, 2000; 81(5): 1223 - 1230. [Abstract] [Full Text]

				A. Seth, I. Ourmanov, J. E. Schmitz, M. J. Kuroda, M. A. Lifton, C. E. Nickerson, L. Wyatt, M. Carroll, B. Moss, D. Venzon, et al. Immunization with a Modified Vaccinia Virus Expressing Simian Immunodeficiency Virus (SIV) Gag-Pol Primes for an Anamnestic Gag-Specific Cytotoxic T-Lymphocyte Response and Is Associated with Reduction of Viremia after SIV Challenge J. Virol., March 15, 2000; 74(6): 2502 - 2509. [Abstract] [Full Text]

				I. Ourmanov, C. R. Brown, B. Moss, M. Carroll, L. Wyatt, L. Pletneva, S. Goldstein, D. Venzon, and V. M. Hirsch Comparative Efficacy of Recombinant Modified Vaccinia Virus Ankara Expressing Simian Immunodeficiency Virus (SIV) Gag-Pol and/or Env in Macaques Challenged with Pathogenic SIV J. Virol., March 15, 2000; 74(6): 2740 - 2751. [Abstract] [Full Text]

				J. C. Ramírez, M. M. Gherardi, and M. Esteban Biology of Attenuated Modified Vaccinia Virus Ankara Recombinant Vector in Mice: Virus Fate and Activation of B- and T-Cell Immune Responses in Comparison with the Western Reserve Strain and Advantages as a Vaccine J. Virol., January 1, 2000; 74(2): 923 - 933. [Abstract] [Full Text]

				D. C. Tscharke and G. L. Smith A model for vaccinia virus pathogenesis and immunity based on intradermal injection of mouse ear pinnae J. Gen. Virol., October 1, 1999; 80(10): 2751 - 2755. [Abstract] [Full Text]

				T. Hanke, R. V. Samuel, T. J. Blanchard, V. C. Neumann, T. M. Allen, J. E. Boyson, S. A. Sharpe, N. Cook, G. L. Smith, D. I. Watkins, et al. Effective Induction of Simian Immunodeficiency Virus-Specific Cytotoxic T Lymphocytes in Macaques by Using a Multiepitope Gene and DNA Prime-Modified Vaccinia Virus Ankara Boost Vaccination Regimen J. Virol., September 1, 1999; 73(9): 7524 - 7532. [Abstract] [Full Text]

				A Alcami, A Khanna, N. Paul, and G. Smith Vaccinia virus strains Lister, USSR and Evans express soluble and cell- surface tumour necrosis factor receptors J. Gen. Virol., April 1, 1999; 80(4): 949 - 959. [Abstract]

				I. M. Belyakov, L. S. Wyatt, J. D. Ahlers, P. Earl, C. D. Pendleton, B. L. Kelsall, W. Strober, B. Moss, and J. A. Berzofsky Induction of a Mucosal Cytotoxic T-Lymphocyte Response by Intrarectal Immunization with a Replication-Deficient Recombinant Vaccinia Virus Expressing Human Immunodeficiency Virus 89.6 Envelope Protein J. Virol., October 1, 1998; 72(10): 8264 - 8272. [Abstract] [Full Text] [PDF]

				A. Seth, I. Ourmanov, M. J. Kuroda, J. E. Schmitz, M. W. Carroll, L. S. Wyatt, B. Moss, M. A. Forman, V. M. Hirsch, and N. L. Letvin Recombinant modified vaccinia virus Ankara-simian immunodeficiency virus gag pol elicits cytotoxic T lymphocytes in rhesus monkeys detected by a major histocompatibility complex class I/peptide tetramer PNAS, August 18, 1998; 95(17): 10112 - 10116. [Abstract] [Full Text] [PDF]